ArticleFrontiers in oncology2018

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.

Gabriela Galicia-Vázquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.